Last updated on September 2016

A Single Arm Phase IV Study of Afatinib in Elderly Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Whose Tumors Have Epidermal Growth Factor Receptor (EGFR) Exon 19 Deletions or Exon 21(L858R) Substitution Mutations

Other Details:

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02514174

Contact: Boehringer Ingelheim Call Center 1-800-243-0127

Find a site near you

Start Over

Lankenau Medical Center

Cancer Center, 100 East Lancaster Ave Wynnewood, PA USA
  Connect »

Drexel University College of Medicine

245 N. 15th Street, 8th Fl Philadelphia, PA USA
  Connect »